SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03893357

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Retrospective Study of the Prevalence of Antiphospholipid Antibodies in the Population of Hemodialysis Patients at the CHU Brugmann Hospital

In patients with a chronic renal disease at the terminal stage, extrarenal epuration is essential for the control of clinico-biological complications. Two extrarenal epuration techniques are currently available: peritoneal dialysis (using the peritoneal membrane of the patient) and hemodialysis, requiring the use of an external biocompatible membrane known as 'dialysis filter'. This technique requires a vascular access (arteriovenous fistula or dialysis catheter). The thrombosis of vascular accesses represents a major cause of morbidity and mortality in hemodialysis patients. Thrombosis are more frequent when using synthetic prosthetic arteriovenous fistula instead of native arteriovenous fistula. Antiphospholipid Syndrome (APLS) is a rare autoimmune disease characterized by arterial thrombosis, venous thrombosis and obstetrical complications such as as defined by the Sidney's criteria. In the general population, the presence of antiphospholipid antibodies is associated with an increased risk of thromboembolic events. In the nephrological population, this prevalence is higher in hemodialysis patients compared to patients on peritoneal dialysis or non-dialyzed patients. Up to 37% of hemodialysis patients are positive for antiphospholipid antibodies and this biology is associated with thrombotic events and vascular access thromboses. However, some studies do not report this association and there is currently no consensus in terms of the therapeutic management of these patients. Some factors influencing the positivity for antiphospholipid antibodies have been reported: smoking, age, the presence of a non-glomerular nephropathy, hypoalbuminaemia, the use of a central venous catheter for dialysis or the use of a non-biocompatible dialysis membrane. Taking into account the conflicting data from the literature, it seems important to study the respective role(s) of 3 types of antiphospholipid antibodies in the occurrence of thrombo- embolic events in patients undergoing dialysis within the CHU Brugmann Hospital.

NCT03893357 Antiphospholipid Syndrome
MeSH: Antiphospholipid Syndrome

1 Interventions

Name: Data extraction from medical files

Description: Retrospective data extraction from the medical files

Type: Other

Positive for antiphospholipid antibodies Negative for antiphospholipid antibodies


Primary Outcomes

Description: Prevalence of antiphospholipid antibodies

Measure: Prevalence of antiphospholipid antibodies

Time: 19 years

Description: Prevalence of arterial thrombosis

Measure: Prevalence of arterial thrombosis

Time: 19 years

Description: Prevalence of venous thrombosis

Measure: Prevalence of venous thrombosis

Time: 19 years

Description: Maturation delay of the arteriovenous fistula

Measure: Maturation delay of the arteriovenous fistula

Time: 19 years

Description: Percentage of thrombosis of the filter

Measure: Percentage of thrombosis of the filter

Time: 19 years

Description: Lifespan of the catheter

Measure: Lifespan of the catheter

Time: 19 years

Description: Lifespan of the fistula

Measure: Lifespan of the fistula

Time: 19 years

Secondary Outcomes

Description: Existence of at least one of the following pro-thrombotic risk factors: smoking, active neoplasia, arterial hypertension.

Measure: Existence of thrombosis risk factors

Time: 19 years

Description: Existence of an anticoagulant treatment Presence of an anticoagulant treatment by means of anti-vitamin K

Measure: Anticoagulant treatment

Time: 19 years

Description: Existence of an antiplatelet treatment

Measure: Antiplatelet treatment Antiplatelet treatment

Time: 19 years

Description: Existence of an antihypertensive treatment

Measure: Antihypertensive treatment

Time: 19 years

Description: Existence of a treatment by means of statins

Measure: Statin treatment

Time: 19 years

Description: Known versus unknown ethiology

Measure: Ethiology of the nephropathy (known/unknown)

Time: 19 years

Description: Glomerular versus non-glomerular ethiology

Measure: Ethiology of the nephropathy (glomerular)

Time: 19 years

Description: Age at dialysis entry

Measure: Age at dialysis entry

Time: 19 years

Description: Catheter versus distal arteriovenous fistula versus proximal arteriovenous fistula

Measure: Vascular access

Time: 19 years

Description: Hemodiafiltration versus conventional hemodialysis

Measure: Type of dialysis

Time: 19 years

Description: With or without heparin

Measure: Type of per-dialytic anticoagulation

Time: 19 years

Description: Brand of dialysis membrane

Measure: Brand of dialysis membrane

Time: 19 years

Description: Urea change percentage

Measure: Urea change percentage

Time: Last available result within 19 years

Description: Coagulation assessment

Measure: Activated partial thromboplastin time (aPTT)

Time: Last available result within 19 years

Description: Hemoglobin count

Measure: Hemoglobin count

Time: Last available result within 19 years

Description: Platelets count

Measure: Platelets count

Time: Last available result within 19 years

Time Perspective: Retrospective

Cohort


There is one SNP

SNPs


1 G20210A

Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Antiphospholipid Syndrome Antiphospholipid Syndrome null --- G20210A ---

Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Antiphospholipid Syndrome Antiphospholipid Syndrome null --- G20210A --- --- G20210A ---



HPO Nodes